A5068206998- Cancer Immunotherapy and Biomarkers
- Ferroptosis and cancer prognosis
- Bladder and Urothelial Cancer Treatments
- Cancer Genomics and Diagnostics
- Lung Cancer Treatments and Mutations
- Human Mobility and Location-Based Analysis
- Single-cell and spatial transcriptomics
- Robotics and Automated Systems
- Sensor Technology and Measurement Systems
- Image and Signal Denoising Methods
- Cell Image Analysis Techniques
- Data Visualization and Analytics
- AI in cancer detection
- Simulation Techniques and Applications
- Mobile Crowdsensing and Crowdsourcing
Icahn School of Medicine at Mount Sinai
2016-2018
Combination immune checkpoint blockade has demonstrated promising benefit in lung cancer, but predictors of response to combination therapy are unknown. Using whole-exome sequencing examine non-small-cell cancer (NSCLC) treated with PD-1 plus CTLA-4 blockade, we found that high tumor mutation burden (TMB) predicted improved objective response, durable benefit, and progression-free survival. TMB was independent PD-L1 expression the strongest feature associated efficacy multivariable analysis....
Background Inhibition of programmed death-ligand 1 (PD-L1) with atezolizumab can induce durable clinical benefit (DCB) in patients metastatic urothelial cancers, including complete remissions chemotherapy refractory disease. Although mutation load and PD-L1 immune cell (IC) staining have been associated response, they lack sufficient sensitivity specificity for use. Thus, there is a need to evaluate the peripheral blood environment conduct detailed analyses load, predicted neoantigens,...
Abstract Robust quantification of immune cell infiltration into the tumor microenvironment may shed light on why only a small proportion patients benefit from checkpoint therapy. The cells surrounding have been suggested to mediate an effective response immunotherapy. However, traditional measurement content around by immunohistochemistry, flow cytometry, or mass cytometry allows up few dozen markers at time, limiting number types identified. Immune type abundances instead be estimated in...
The PlaceIQ platform is a large-scale data analysis system created on the concept of location. This paper overview where we provide an description nature sources, frame reference, abstractions, algorithmic approaches, as well main design tradeoffs this system. We also list some lessons learned after deploying and using for numerous actual mobile advertisement campaigns. Additionally, describe Place Visit Rate, which location-based criterion quantifying campaign response. believe that lift...
Abstract Background: Inhibition of programmed death-ligand one (PD-L1) with atezolizumab can induce durable clinical benefit (DCB) in patients metastatic urothelial cancers, including complete remissions chemotherapy refractory disease. Although mutation load and PD-L1 immune cell (IC) staining have been associated response, they lack sufficient sensitivity specificity for use. Thus, there is a need to evaluate the peripheral blood environment conduct detailed analyses load, predicted...